BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Given Consensus Recommendation of “Buy” by Analysts

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) have received an average recommendation of “Buy” from the six analysts that are covering the company, MarketBeat.com reports. Six equities research analysts have rated the stock with a buy rating. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $13.83.

Separately, Needham & Company LLC reissued a “buy” rating and issued a $12.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Wednesday, April 10th.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

Large investors have recently added to or reduced their stakes in the business. Fifth Third Bancorp increased its stake in BioCryst Pharmaceuticals by 17,500.0% during the 3rd quarter. Fifth Third Bancorp now owns 3,520 shares of the biotechnology company’s stock worth $25,000 after buying an additional 3,500 shares during the period. China Universal Asset Management Co. Ltd. grew its holdings in BioCryst Pharmaceuticals by 96.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 4,865 shares of the biotechnology company’s stock worth $34,000 after acquiring an additional 2,388 shares in the last quarter. Quarry LP acquired a new position in BioCryst Pharmaceuticals during the 4th quarter worth approximately $54,000. Tower Research Capital LLC TRC grew its holdings in BioCryst Pharmaceuticals by 131.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 10,420 shares of the biotechnology company’s stock worth $62,000 after acquiring an additional 5,912 shares in the last quarter. Finally, JGP Global Gestao de Recursos Ltda. acquired a new position in BioCryst Pharmaceuticals during the 4th quarter worth approximately $64,000. 85.88% of the stock is owned by hedge funds and other institutional investors.

BioCryst Pharmaceuticals Price Performance

Shares of BCRX opened at $4.41 on Tuesday. BioCryst Pharmaceuticals has a 1-year low of $4.27 and a 1-year high of $9.06. The stock has a market cap of $909.12 million, a PE ratio of -3.74 and a beta of 1.90. The firm has a 50-day simple moving average of $5.18 and a two-hundred day simple moving average of $5.58.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings results on Monday, February 26th. The biotechnology company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.04). The business had revenue of $93.40 million for the quarter, compared to analyst estimates of $89.19 million. As a group, sell-side analysts expect that BioCryst Pharmaceuticals will post -0.68 earnings per share for the current fiscal year.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.